338 related articles for article (PubMed ID: 27672288)
1. HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.
Fusco N; Bosari S
World J Gastroenterol; 2016 Sep; 22(35):7926-37. PubMed ID: 27672288
[TBL] [Abstract][Full Text] [Related]
2. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.
El Dika I; Ilson DH
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1085-1092. PubMed ID: 30092682
[TBL] [Abstract][Full Text] [Related]
3. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
4. Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.
Zheng-Lin B; Graham RP; Bekaii-Saab TS
Chin Clin Oncol; 2023 Oct; 12(5):55. PubMed ID: 37964543
[TBL] [Abstract][Full Text] [Related]
5. Obesity-associated digestive cancers: A review of mechanisms and interventions.
Zheng J; Zhao M; Li J; Lou G; Yuan Y; Bu S; Xi Y
Tumour Biol; 2017 Mar; 39(3):1010428317695020. PubMed ID: 28351315
[TBL] [Abstract][Full Text] [Related]
6. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
Treacy AD; Karamchandani JR; Streutker CJ; Grin A
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
[TBL] [Abstract][Full Text] [Related]
7. Sentinel lymph node biopsy in gastrointestinal malignancies-where do we stand?
Maharaj R; Shukla PJ; Naraynsingh V; Dan D; Hariharan S
Indian J Cancer; 2011; 48(3):345-50. PubMed ID: 21921336
[TBL] [Abstract][Full Text] [Related]
8. HER2/neu-directed therapy for biliary tract cancer.
Javle M; Churi C; Kang HC; Shroff R; Janku F; Surapaneni R; Zuo M; Barrera C; Alshamsi H; Krishnan S; Mishra L; Wolff RA; Kaseb AO; Thomas MB; Siegel AB
J Hematol Oncol; 2015 May; 8():58. PubMed ID: 26022204
[TBL] [Abstract][Full Text] [Related]
9. Established and Potential Predictive Biomarkers in Gastrointestinal Cancer--c-Kit, Her2, Ras and Beyond.
Koch C; Trojan J
Digestion; 2015; 91(4):294-302. PubMed ID: 25924988
[TBL] [Abstract][Full Text] [Related]
10. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
11. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
12. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
13. Survival of Danish cancer patients 1943-1987. Digestive organs.
Johansen C; Soll-Johanning H; Kolstad H; Lynge E; Carstensen B
APMIS Suppl; 1993; 33():35-76. PubMed ID: 8512741
[TBL] [Abstract][Full Text] [Related]
14. Experimental HER2- targeted therapies for biliary tract cancer.
Rizzo A; Ricci AD; Bonucci C; Tober N; Palloni A; Frega G; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):389-399. PubMed ID: 33218269
[No Abstract] [Full Text] [Related]
15. The functional role of long non-coding RNA in digestive system carcinomas.
Wang GY; Zhu YY; Zhang YQ
Bull Cancer; 2014 Sep; 101(9):E27-31. PubMed ID: 25295496
[TBL] [Abstract][Full Text] [Related]
16. Oncocytic and oncocytoid tumors of the exocrine pancreas, liver, and gastrointestinal tract.
Papotti M; Cassoni P; Taraglio S; Bussolati G
Semin Diagn Pathol; 1999 May; 16(2):126-34. PubMed ID: 10452578
[TBL] [Abstract][Full Text] [Related]
17. Applicability and interpretation of HER2/Neu & PD-L1 stains in gastrointestinal tract tumours.
Das P; Mehra L
Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S2-S3. PubMed ID: 34135132
[TBL] [Abstract][Full Text] [Related]
18. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF; Polydorides AD
Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
[TBL] [Abstract][Full Text] [Related]
19. Targeted HER2 treatment in advanced gastric cancer.
Jørgensen JT
Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
[TBL] [Abstract][Full Text] [Related]
20. Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature.
May M; Raufi AG; Sadeghi S; Chen K; Iuga A; Sun Y; Ahmed F; Bates S; Manji GA
Oncologist; 2021 Aug; 26(8):640-646. PubMed ID: 33896096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
